New chickenpox vaccine shows promise in large Kids' trial
NCT ID NCT07054099
First seen Apr 22, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests a new chickenpox vaccine (MG1111) in healthy children aged 1 to 12 years. It compares the new vaccine's safety and immune response to the current standard vaccine. About 474 children will receive two doses and be monitored for 42 days, with long-term follow-up for up to 10 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VARICELLA (CHICKENPOX) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Srinagarind Hospital
RECRUITINGKhon Kaen, Changwat Khon Kaen, 40002, Thailand
Conditions
Explore the condition pages connected to this study.